Earnings summaries and quarterly performance for PHIBRO ANIMAL HEALTH.
Executive leadership at PHIBRO ANIMAL HEALTH.
Jack Bendheim
Detailed
Chairman, President and Chief Executive Officer
CEO
AA
Anthony Andolino
Detailed
Vice President Finance and Treasurer
DB
Daniel Bendheim
Detailed
Executive Vice President, Corporate Strategy
GD
Glenn David
Detailed
Chief Financial Officer
JW
Judith Weinstein
Detailed
Senior Vice President, General Counsel and Corporate Secretary
LM
Larry Miller
Detailed
Chief Operating Officer
LE
Lisa Escudero
Detailed
Senior Vice President, Human Resources
Board of directors at PHIBRO ANIMAL HEALTH.
Research analysts who have asked questions during PHIBRO ANIMAL HEALTH earnings calls.
EK
Ekaterina Knyazkova
Cantor Fitzgerald
6 questions for PAHC
Also covers: AMPH, ANIP, ELAN
Michael Ryskin
Bank of America Merrill Lynch
6 questions for PAHC
Also covers: A, ALGN, AVTR +28 more
NT
Navann Ty
BNP Paribas S.A.
5 questions for PAHC
Also covers: COO, ELAN, EOLS +4 more
LB
Linda Bolduc
Morgan Stanley
3 questions for PAHC
Also covers: BTSG, ELAN
NT
Navann Ty Dietschi
BNP Paribas
3 questions for PAHC
Also covers: COO, ELAN, EOLS +6 more
BP
Balaji Prasad
Barclays
1 question for PAHC
Also covers: ALVO, AMRX, ELAN +7 more
EW
Erin Wright
Morgan Stanley
1 question for PAHC
Also covers: ALGN, BTSG, CAH +18 more
Recent press releases and 8-K filings for PAHC.
Phibro Animal Health Corporation Reports Strong Q2 2026 Results and Raises Full-Year Guidance
PAHC
Earnings
Guidance Update
Management Change
- Phibro Animal Health Corporation reported strong Q2 2026 financial results, with consolidated net sales increasing 21% to $373.9 million and adjusted EBITDA growing 41%.
- The Animal Health segment was a key driver, with sales up 26%, primarily due to 34% growth in Medicated Feed Additives from the successful integration of the new MFA business.
- The company raised its full-year fiscal 2026 guidance, now expecting net sales between $1.45 billion and $1.5 billion and adjusted EBITDA between $245 million and $255 million.
- Gross margins improved significantly, driven by additional pricing, a positive product mix (nutritional specialties and vaccines), and a focus on higher-margin offerings.
- Donnie Bendheim will assume the CEO role in July, with Jack Bendheim transitioning to Executive Chairman, ensuring leadership continuity and building on current momentum.
1 day ago
Phibro Animal Health Corporation Reports Strong Q2 2026 Results and Raises Full-Year Guidance
PAHC
Earnings
Guidance Update
Management Change
- Phibro Animal Health Corporation reported strong Q2 fiscal year 2026 results, with consolidated net sales increasing 21% to $373.9 million and adjusted EBITDA rising 41%.
- The Animal Health segment's sales grew 26%, primarily driven by 34% growth in Medicated Feed Additives due to the successful integration of the new MFA business.
- The company raised its full-year fiscal 2026 guidance for net sales to $1.45 billion-$1.5 billion, adjusted EBITDA to $245 million-$255 million, and adjusted net income to $120 million-$127 million.
- Donnie Bendheim is set to become CEO in July, while Jack Bendheim will continue as executive chairman.
1 day ago
Phibro Animal Health Corporation Announces Strong Q2 FY26 Results and Updates Full-Year Guidance
PAHC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Phibro Animal Health Corporation reported Q2 FY26 consolidated Net Sales of $373.9 million, a 21% year-over-year increase, and Adjusted EBITDA of $68.1 million, up 41%.
- The Animal Health segment demonstrated strong performance in Q2 FY26, with Net Sales growing 26% to $290.0 million and Adjusted EBITDA increasing 41% to $82.2 million.
- The company updated its FY2026 guidance, now expecting Net Sales between $1.450 billion and $1.500 billion, Adjusted EBITDA between $245 million and $255 million, and Adjusted Diluted EPS between $2.93 and $3.10.
- As of December 31, 2025, free cash flow was $47 million for the trailing twelve months, with a net leverage ratio of 2.8x.
1 day ago
Phibro Animal Health Reports Strong Q2 2026 Results, Raises FY26 Guidance, and Announces CEO Designate
PAHC
Earnings
Guidance Update
Management Change
- Phibro Animal Health Corporation reported strong Q2 2026 financial results, with consolidated net sales increasing 21% to $373.9 million and adjusted EBITDA rising 41%.
- The Animal Health segment sales grew 26% to $290 million, primarily driven by 34% growth in Medicated Feed Additives, which included a $94.1 million contribution from the new MFA business.
- The company raised its full-year fiscal 2026 guidance, now projecting net sales between $1.45 billion and $1.5 billion and adjusted EBITDA between $245 million and $255 million.
- This strong performance and updated outlook are attributed to the successful integration of the new MFA business, improved gross margins from favorable mix and pricing, and the ongoing Phibro Forward strategy.
- Donnie Bendheim has been announced as CEO Designate, scheduled to assume the role in July, with Jack Bendheim continuing as Executive Chairman.
1 day ago
Phibro Animal Health Corporation Reports Strong Q2 2026 Results and Raises Full-Year Guidance
PAHC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Phibro Animal Health Corporation announced strong financial results for the second quarter ended December 31, 2025, with net sales increasing 21% to $373.9 million and diluted earnings per share rising to $0.67.
- The company's Adjusted EBITDA grew 41% to $68.1 million for the quarter, attributed to faster than expected uptake of the newly integrated MFA portfolio and sustained growth in nutritional specialty and vaccine offerings.
- Phibro Animal Health Corporation raised its fiscal year 2026 guidance, now projecting net sales between $1.45 billion and $1.50 billion and Adjusted EBITDA between $245 million and $255 million.
2 days ago
Phibro Animal Health Corporation Reports Strong Q2 FY2026 Results and Raises Full-Year Guidance
PAHC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Phibro Animal Health Corporation reported strong second-quarter results for the period ended December 31, 2025, with net sales increasing 21% to $373.9 million, net income rising to $27.5 million, and Adjusted EBITDA growing 41% to $68.1 million.
- The company's performance was significantly boosted by the faster-than-expected uptake of its newly integrated MFA portfolio, which contributed $57.5 million in incremental revenues, alongside continued strong growth in nutritional specialty and vaccine offerings.
- Based on this momentum, Phibro Animal Health Corporation raised its fiscal year 2026 guidance, now projecting net sales of $1.45 billion to $1.50 billion and Adjusted EBITDA of $245 million to $255 million.
2 days ago
Phibro Animal Health Corporation Announces Strong Q1 FY2026 Results and Reaffirms FY2026 Guidance
PAHC
Earnings
Guidance Update
Product Launch
- Phibro Animal Health Corporation reported robust Q1 FY2026 consolidated financial results, with Net Sales increasing 40% to $363.9 million and Adjusted EBITDA growing 102% to $61.9 million compared to the prior year period.
- The Animal Health segment was a significant driver of performance, with sales increasing 55% to $283.5 million and Adjusted EBITDA growing 85% to $74.9 million in Q1 FY2026.
- The company reiterated its FY2026 guidance, projecting Net Sales between $1.425 billion and $1.475 billion and Adjusted EBITDA between $230 million and $240 million.
- Phibro launched Restoris™, a new therapeutic compound for canine periodontal care, and licensed an early-stage drug compound targeting periodontal disease.
Nov 6, 2025, 2:00 PM
Phibro Animal Health Reports Strong Q1 2026 Results and Raises Full-Year Earnings Guidance
PAHC
Earnings
Guidance Update
Product Launch
- For the first quarter ending September 30, 2025, Phibro Animal Health Corporation reported consolidated net sales of $363.9 million, a 40% increase over the prior year, and adjusted EBITDA increased by 102%.
- The Animal Health segment grew 55%, driven by an 81% increase in Medicated Feed Additives (MFA), which included $80.5 million from the new MFA business and 6% growth in legacy MFA.
- The company raised its full-year fiscal 2026 guidance for total adjusted EBITDA to $230 million - $240 million and adjusted net income to $108 million - $115 million, while net sales guidance remained unchanged at $1,425 million - $1,475 million.
- Phibro launched Restoris, a proprietary dental gel for dogs, and licensed an early-stage therapeutic compound, marking a significant step in its companion animal strategy.
Nov 6, 2025, 2:00 PM
Phibro Animal Health Corporation Reports Strong Q1 2026 Results, Raises FY 2026 Adjusted EBITDA Guidance
PAHC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Phibro Animal Health Corporation reported net sales of $363.9 million for the first quarter ended September 30, 2025, marking a 40% increase compared to the prior year, primarily driven by a 55% rise in Animal Health net sales.
- For Q1 2026, the company achieved net income of $26.5 million and diluted income per share of $0.65, representing increases of $19.6 million and $0.48, respectively.
- Adjusted EBITDA grew by $31.2 million to $61.9 million for the quarter, and Adjusted diluted EPS doubled to $0.73.
- The company raised its fiscal year 2026 Adjusted EBITDA guidance to $230 million to $240 million, while reaffirming its net sales guidance of $1.43 billion to $1.48 billion.
- Phibro also announced the national launch of Restoris™, a new dental gel for dogs, establishing a new portfolio in companion animal oral health.
Nov 5, 2025, 9:35 PM
Phibro Animal Health Corporation Reports Strong Q4 and Full-Year Results, Provides FY 2026 Guidance
PAHC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Phibro Animal Health Corporation reported strong financial results for the fourth quarter ended June 30, 2025, with net sales increasing 39% to $378.7 million and adjusted diluted EPS rising 39% to $0.57.
- For the full fiscal year ended June 30, 2025, net sales grew 27% to $1,296.2 million and adjusted EBITDA increased 65% to $183.7 million.
- The company attributed the growth to sustained demand across MFAs, nutritional specialties, and vaccines, with the Zoetis MFA portfolio contributing to a 54% year-over-year increase in MFA and Other product sales.
- Phibro provided financial guidance for the fiscal year ending June 30, 2026, projecting net sales of $1.43 billion to $1.48 billion and adjusted EBITDA of $225 million to $235 million.
Aug 27, 2025, 12:00 AM
Quarterly earnings call transcripts for PHIBRO ANIMAL HEALTH.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more